Skip to content
  • About
  • Team
  • Clinical Trials
  • KRN-101
  • Investing
  • Press & Updates
  • Contact
Menu
  • About
  • Team
  • Clinical Trials
  • KRN-101
  • Investing
  • Press & Updates
  • Contact
CSE: ABRT • FSE: VB50
CSE: ABRT
ABRT
  • About
  • Team
  • Clinical Trials
  • KRN-101
  • Investing
  • Press & Updates
  • Contact
Menu
  • About
  • Team
  • Clinical Trials
  • KRN-101
  • Investing
  • Press & Updates
  • Contact
CSE: ABRT • FSE: VB50
CSE: ABRT
ABRT

Our Technology

The science of natural pharmaceuticals demands precision. In collaboration with leading scientists and research partners from around the world, we develop research-backed medicines derived from patented technologies to treat mental health better.

KRN-101 is derived from natural psilocybin mycelium

Medical innovation through natural fungi is nothing new. In fact, fungi have been pharmaceutically prolific in modern medicine from the antibiotic instrumental across the world – penicillin, to the cancer medication taxol. Psilocybin has the potential to be the next great pharmaceutical breakthrough in the war on mental health.

Fungi’s metabolic ingenuity provides ample opportunity to tackle today’s biggest healthcare challenges.

Psilocybin was produced by fungi for tens of millions of years before humans evolved – the current best estimate puts the origin of the first psilocybin producing mushroom at around 75 million years ago.

Microscope

Translating nature into medicine

Mycelium is often labelled as the roots of a mushroom when in reality they’re more like the tree itself with mushrooms as its fruit. We are focused on mycological research, understanding not just the psilocybin producing mushrooms but also the cultivation of mycelium. Our patent-pending process makes use of bioreactors to produce consistent quality and scalable quantities of fungi mycelia.

Albert Labs’ research laboratories have licences to produce, distribute and sell product to the international market. Using patent-pending technology Albert Labs produce precision natural medicines to treat mental health.

An estimated 3.8 million fungi species exist worldwide [1] 

More than 90% of fungi species are still unknown to science [2] 

Genetically, fungi are more closely related to animals than plants [3] 

180 psilocybin-containing mushrooms species are found around the world [4] 

The unexplored wonder of the world

History has shown that fungi have played a fundamental role to all life on earth. With the oldest evidence of mycelium dating back 2.4bn years ago, 2bn years before animals walked the earth. [5]  In the science community, it is well considered that despite their importance to life’s evolution itself, fungi are still one of the most unexplored wonders of the biological world. World-renowned biologist Merlin Sheldrake goes as far to say “The more we learn about fungi, the less the world makes sense without them.” Fungi’s role in nature doesn’t just date back millennia it is instrumental to life today, from yeast to make bread and beer, to natural pesticides and antibiotic medicines. The ability for mycelium to prosper in this way comes down to their diverse metabolic abilities. Think of metabolism as the art of chemical transformation. It is this ingenuity that Albert Labs are leveraging to discover new drugs. [6] 
The Unmet Need

Natural vs Synthetic

Patients

Preferred by patients

Its not only natural and organic foods people prefer, the trend for natural and alternative medicine is on the rise.

Earth

Good for the planet

Utilising mycelium's natural ability to digest minerals and nutrients. Albert Labs' technology saves on energy as well as greatly reduces the reliance on synthetic chemicals.

Chemicals

Fewer by-products

The natural bio-synthesis of psilocybin, psilocin and many other metabolites can be produced with fewer by-products and chemical residues.

Economic

Economic manufacture

Growing mycelium naturally with minerals and nutrients results in a reduced reliance on expensive chemicals and energy.

Innovative mental health medicines for patients with unmet needs

  • Legal Disclaimer
  • Privacy Policy
  • Modern Slavery Statement
  • Cookie Policy
  • Legal Disclaimer
  • Privacy Policy
  • Modern Slavery Statement
  • Cookie Policy

© 2022 Albert Labs. All Rights Reserved

  • About
  • Team
  • Clinical Trials
  • KRN-101
  • Investing
  • Press & Updates
  • Contact
  • About
  • Team
  • Clinical Trials
  • KRN-101
  • Investing
  • Press & Updates
  • Contact
Twitter Linkedin Youtube Envelope
CSE:ABRT
FSE: VB50
CSE:ABRT
FSE: VB50

About Albert Labs

We are a pharmaceutical company leveraging our drug development and clinical research expertise to accelerate the development of highly effective mental health medicines.

If you would like support or more information around making an investment, please contact investing@albertlabs.com

Twitter Linkedin Youtube Envelope

Complete this form to receive corporate updates and further details on how to invest in Albert Labs. By completing this form, you agree to our privacy policy.

Twitter
Youtube
Linkedin
Instagram
Envelope

Latest Press Release

Albert Labs Announces Private Placement

Read more
Twitter
Youtube
Linkedin
Instagram
Envelope

Latest Press Release

Albert Labs Announces Private Placement

Read more

By completing this form you agree to our privacy policy. You will be sent corporate updates and further details including how to invest in Albert Labs.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok